Staar Surgical: Sidoti Downgrades Neutral, Raises PT to $28

Staar Surgical: Sidoti Downgrades Neutral, Raises PT to $28

Title: Staar Surgical: Sidoti Downgrades Neutral, Raises PT to $28

Staar Surgical Co. (STAA) experienced a significant change in its market outlook following a recent downgrade from Sidoti Research. The firm has revised its price target for STAA to $28, indicating a potential upside of 124.01% from the current price of $18.49 [3]. This move comes amidst a series of positive and negative signals surrounding the stock.

On Monday, August 4, 2025, STAA's stock price gained 4.11%, rising from $17.76 to $18.49. The stock has shown a mixed trend in the short term, with a 4.11% gain over the past two weeks. The trading volume increased significantly, with 535,000 more shares traded compared to the previous day, totaling 1 million shares traded for approximately $22.50 million [1].

Technical analysts have provided a mixed forecast for STAA. While the stock holds several buy signals from both short and long-term moving averages, there are also indications of potential short-term falls. The stock is expected to fall by -5.14% over the next three months, with a 90% probability of holding a price between $15.02 and $18.17 at the end of this period [1].

The stock has shown resilience, finding support at $17.76 and $18.47. However, a breakdown below these levels could issue sell signals. Additionally, the stock had a Golden Star Signal on July 17, 2025, which is a rare combination of short-term and long-term moving averages meeting the price line, often followed by long and strong gains [1].

Staar Surgical Co. is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $40.67 million, with earnings expected to be -$0.66 per share. The full year 2025 revenue is expected to be $255.27 million, with earnings estimated at -$1.73 per share [2].

The company has also entered into a definitive agreement and plan of merger with Alcon Research, LLC. Alcon will acquire STAA for $28.00 per share in an all-cash transaction, with the deal expected to close by August 4, 2026. STAA's stock will be delisted from NASDAQ post-close, and the company will continue to exist as a wholly owned subsidiary [3].

Despite the mixed signals and the upcoming merger, Sidoti Research has raised its price target for STAA to $28, indicating a potential upside. Investors should closely monitor the earnings report and the progress of the merger for further insights into STAA's future performance.

References
[1] https://stockinvest.us/stock/STAA
[2] https://finance.yahoo.com/news/staar-surgical-co-staa-q2-140137202.html
[3] https://www.stocktitan.net/sec-filings/STAA/8-k-staar-surgical-co-reports-material-event-810347cabb0b.html